Ocugen (OCGN) Expected to Announce Earnings on Tuesday

Ocugen (NASDAQ:OCGN) is anticipated to post its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect Ocugen to post earnings of ($0.05) per share and revenue of $0.4180 million for the quarter. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 5, 2026 at 8:30 AM ET.

Ocugen (NASDAQ:OCGN) last posted its quarterly earnings results on Wednesday, March 4th. The company reported ($0.06) EPS for the quarter, hitting the consensus estimate of ($0.06). The company had revenue of ($0.19) million for the quarter, compared to the consensus estimate of $0.86 million. Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 2,626.38%. On average, analysts expect Ocugen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ocugen Trading Up 4.0%

OCGN stock opened at $1.80 on Friday. The company has a market capitalization of $609.34 million, a PE ratio of -7.83 and a beta of 2.31. Ocugen has a 12 month low of $0.64 and a 12 month high of $2.73. The firm’s 50-day moving average is $1.88 and its 200 day moving average is $1.59. The company has a debt-to-equity ratio of 8.04, a current ratio of 1.06 and a quick ratio of 1.06.

Analyst Ratings Changes

Several research analysts recently commented on OCGN shares. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 price target on shares of Ocugen in a research note on Wednesday, March 25th. Oppenheimer started coverage on shares of Ocugen in a research note on Wednesday, March 11th. They issued an “outperform” rating and a $10.00 price target on the stock. Canaccord Genuity Group started coverage on shares of Ocugen in a research note on Tuesday, March 17th. They issued a “buy” rating and a $12.00 price target on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ocugen in a research note on Thursday, January 22nd. Finally, HC Wainwright raised their price target on shares of Ocugen from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $9.75.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in OCGN. State Street Corp increased its position in Ocugen by 193.6% during the 4th quarter. State Street Corp now owns 3,978,738 shares of the company’s stock valued at $5,371,000 after purchasing an additional 2,623,361 shares during the period. Marshall Wace LLP purchased a new position in Ocugen during the 4th quarter valued at about $3,417,000. Goldman Sachs Group Inc. increased its position in Ocugen by 2,256.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,302,475 shares of the company’s stock valued at $3,108,000 after purchasing an additional 2,204,765 shares during the period. Renaissance Technologies LLC increased its position in Ocugen by 485.9% during the 4th quarter. Renaissance Technologies LLC now owns 1,700,400 shares of the company’s stock valued at $2,296,000 after purchasing an additional 1,410,200 shares during the period. Finally, Millennium Management LLC increased its position in Ocugen by 29.7% during the 4th quarter. Millennium Management LLC now owns 5,396,417 shares of the company’s stock valued at $7,285,000 after purchasing an additional 1,234,268 shares during the period. Hedge funds and other institutional investors own 10.27% of the company’s stock.

Ocugen Company Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.